01.15.26 -- How Outsourcing Meets Precision: A Formula For CDMO Interactions

This event offers short, interactive digital presentations from leading CDMOs showcasing their capabilities, facilities, and available capacity for biopharma development and fill-finish manufacturing. Attendees can explore sterile filling, lyophilization, and packaging technologies, and ask questions live. Open to pharma and biotech professionals, industry consultants, investment firms, and CDMO sponsors seeking manufacturing solutions. Click here to learn more.

If your product uses cold chain logistics, requires user pipetting, or has a short expiration window, there are significant benefits to introducing a lyophilized version.

Bioanalysis is crucial for biopharma success. Here, Dash Bio’s Ander Tallett discusses selecting a bioanalysis CRO and collaborating effectively for assay results that accelerate drug development.

A thorough and adaptable analytical strategy is essential for navigating the complex mAb market. This approach boosts the likelihood of market approval and unlocks the full potential of these therapies.

2026 is shaping up to be a year in which operational discipline, strategic alignment, and regulatory preparedness will differentiate high-performing sponsors from those facing avoidable delays.

Through early collaboration and advanced aseptic technology, organizations can overcome complex formulation challenges to ensure safe, effective treatments reach patients more efficiently than before.

In this presentation, industry-leading bioprocess experts explore the challenges and opportunities that arise when implementing Quality by Design (QbD) in biologics development and manufacturing.

Experienced outsourcing partners will have the right facility and technical capabilities, a culture of speed and execution, and shared expectations and commitment to continuous improvement.

With a growing interest in developing new and improved bioconjugate drugs, explore an “innovation through collaboration” approach that can facilitate access to next-generation conjugation technologies.

Hear from experienced professionals in the drug delivery space on how to ensure success and speed-to-market by establishing a firm foundation when working with a CMO.

Rapid mRNA drug production is impressive but exposes supply chain gaps, especially for key ingredients like lipids.

To meet mAb and bispecific expression needs, sponsors need proven cell line platforms. KBI's TranspoEase delivers high titer and stability for complex proteins.

As capacity expands and capabilities mature, CDMOs with global scale and advanced injectable expertise are becoming critical partners for bringing complex sterile drug products to market.

Unlock superior performance for peptides and proteins using nanotechnology. Achieve high drug loads for subcutaneous delivery and stable, aerodynamic dry powders for deep-lung inhalation.

Discover how to accelerate development and reduce risk with phase-appropriate analytical methods designed to deliver high-quality data, ensure alignment, and drive smarter decisions.

This solution uses an 8 mm needle combined with a thin-wall cannula to reduce pressure drop and improve flow.

Explore regulatory interest in modern environmental monitoring for aseptic filling, the benefits of biofluorescent particle counters, and their role in enhancing drug product safety and quality.

The largest end-to-end biologics CDMO facility in North America is being built, with a 1M sq. ft. site designed for future growth and flexible expansion to meet emerging partner needs.